As of June 30, 2026, the Company held an equity investment in Aqualung Carbon Capture AS ("Aqualung"), a privately held entity, which is classified as a financial asset measured at fair value through profit or loss in accordance with IFRS 9, Financial Instruments. The fair value of the investment was determined using observable market-based inputs in accordance with IFRS 13, Fair Value Measurement. Aqualung is engaged in the development of carbon capture technology and is based in Norway with operations in the United States.

During the six months ended June 30, 2026, the Company recorded fair value gain of $0.2 million resulting from foreign exchange translation effects.

During the six months ended June 30, 2025, the Company remeasured its investment in Aqualung to $5.4 million to reflect an equity investment transaction that was completed by Aqualung, which the Company did not participate in. The Company

recorded a fair value gain of $2.8 million during the six months ended June 30, 2025, primarily reflecting the impact of an equity financing transaction completed by Aqualung, in which the Company did not participate.